Affimed NV

Ticker AFMD

Exchange NASDAQ More
Industry Biotechnology More
Sector Healthcare More

51-200 Employees
Based in Heidelberg, Germany

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell bispecific antibody (TandAb) that completed Phase I clinical trial for the treatment of various CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma.

Visit website

Social Media Links

REPORT RATINGS

4.8 / 5.0 (93)

Affimed NV reports have an aggregate usefulness score of 4.8 based on 93 reviews.

Affimed NV

Most Recent Annual Report

MOST RECENT 2023 Annual Report

View PDF

Affimed NV does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Please fill out the form below and click "Place Order" to complete your order.